Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

KDM6A (Lysine Demethylase 6A)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 60 Plus Assay

TruSight Myeloid Sequencing Panel

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 60 Plus Assay

TruSight Myeloid Sequencing Panel

›

KDM6A mutation	Gastric Cancer	KDM6A mutation	Gastric Cancer	5-fluorouracil Sensitive: B - Late Trials 5-fluorouracil Sensitive : B	5-fluorouracil Sensitive: B - Late Trials 5-fluorouracil Sensitive : B
MECOM mutation + KDM6A mutation	Myelodysplastic Syndrome	MECOM mutation + KDM6A mutation	Myelodysplastic Syndrome	lenalidomide Sensitive: C3 – Early Trials lenalidomide Sensitive : C3	lenalidomide Sensitive: C3 – Early Trials lenalidomide Sensitive : C3
KDM6A underexpression	Gastric Cancer	KDM6A underexpression	Gastric Cancer	5-fluorouracil Resistant: C3 – Early Trials 5-fluorouracil Resistant : C3	5-fluorouracil Resistant: C3 – Early Trials 5-fluorouracil Resistant : C3
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
TMB-H + KDM6A mutation	Urothelial Cancer	TMB-H + KDM6A mutation	Urothelial Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KDM6A amplification	Prostate Cancer	KDM6A amplification	Prostate Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
KDM6A mutation	Acute Myelogenous Leukemia	KDM6A mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4	cytarabine/daunorubicin liposomal formulation Resistant: C4 – Case Studies cytarabine / daunorubicin liposomal formulation Resistant : C4
KDM6A mutation	Renal Cell Carcinoma	KDM6A mutation	Renal Cell Carcinoma	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D	MRTX2219 Sensitive: D – Preclinical MRTX2219 Sensitive : D